DelveInsight's“ Atopic Dermatitis Pipeline Insight 2025 ” report provides comprehensive insights about 100+ companies and 120+ pipeline drugs in the Atopic Dermatitis pipeline landscape. It covers the ...

Q3 2025 Management View CEO Howard W. Robin welcomed Dr. Mary Tagliaferri back as Chief Medical Officer, noting her previous role in the successful Phase II program in atopic dermatitis and her return ...

Experts discuss the importance of safe, effective topical therapies for long-term management of atopic dermatitis, ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Sure is a lot longer list than it used to ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Incyte has announced promising new data from its phase 3b TRuE-AD4 trial of Opzelura (ruxolitinib cream) in adults with moderate atopic dermatitis (AD), revealing significant improvements in clinical ...

SAN MATEO, Calif. and SINGAPORE, April 30, 2024 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative ...

Once-daily, effective, safe, and well-tolerated ZORYVE cream 0.05% now commercially available for children as young as age 2ZORYVE cream 0.05% ...

Please provide your email address to receive an email when new articles are posted on . Across dose-arms, 71.9% of patients who continued treatment and 57% of patients withdrawn from treatment ...

Eli Lilly and Co. (NYSE:LLY) on Friday shared new results from Ebglyss (lebrikizumab-lbkz) for moderate-to-severe atopic dermatitis. Ebglyss showed sustained similar levels of skin clearance when ...

Nektar Therapeutics (NKTR) showcases financial resilience and advances in its ResPEG program, despite facing market ...

The IGA score, BSA, and DLQI are instruments that Megan Rogge, MD, dermatologist at McGovern Medical School, UTHealth Houston, uses to select and justify treatment options for prior authorization in ...